Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan

BACKGROUND: MVC-COV1901, a recombinant protein vaccine containing pre-fusion-stabilised spike protein S-2P adjuvanted with CpG 1018 and aluminium hydroxide, has been shown to be well tolerated with a good safety profile in healthy adults aged 20–49 years in a phase 1 trial, and provided a good cellu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Szu-Min, Liu, Ming-Che, Chen, Yen-Hsu, Lee, Wen-Sen, Hwang, Shinn-Jang, Cheng, Shu-Hsing, Ko, Wen-Chien, Hwang, Kao-Pin, Wang, Ning-Chi, Lee, Yu-Lin, Lin, Yi-Ling, Shih, Shin-Ru, Huang, Chung-Guei, Liao, Chun-Che, Liang, Jian-Jong, Chang, Chih-Shin, Chen, Charles, Lien, Chia En, Tai, I-Chen, Lin, Tzou-Yien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514195/
https://www.ncbi.nlm.nih.gov/pubmed/34655522
http://dx.doi.org/10.1016/S2213-2600(21)00402-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514195/
https://www.ncbi.nlm.nih.gov/pubmed/34655522
http://dx.doi.org/10.1016/S2213-2600(21)00402-1

Ejemplares similares